

Abstract

The present invention provides a method of treatment of thrombotic thrombocytopenic purpura (TTP) and
5 hemolytic uremic syndrome (HUS) with protein C. The claimed invention provides a needed therapy for a potentially serious and debilitating disorder while avoiding complications such as bleeding tendency, toxicity and general side effects of plasma exchange or currently
10 available anti-coagulant agents.